115
Participants
Start Date
October 1, 2018
Primary Completion Date
August 17, 2023
Study Completion Date
August 17, 2023
DCCR
Once daily oral administration of open-label DCCR tablet(s) during the OLE Period
DCCR
Once daily oral administration of double-blind (DCCR) tablet(s) during the RW Period
Placebo for DCCR
Once daily oral administration of double-blind (placebo for DCCR) tablet(s) during the RW Period
NYU Winthrop Hospital, Mineola
National Institutes of Health Hatfield Clinical Research Center, Bethesda
Emory Children's Center, Atlanta
University of Florida Gainesville, Gainesville
Vanderbilt University, Nashville
The Research Institute at Nationwide Children's Hospital, Columbus
University Hospitals Cleveland Medical Center, Cleveland
Indiana University School of Medicine, Indianapolis
Sparrow Clinical Research Institute, Lansing
Children's Minnesota, Saint Paul
Kansas University Medical Center, Kansas City
Research Institute of Dallas, Dallas
Children's Hospital Colorado, Aurora
University of Utah, Salt Lake City
Rady Children's Hospital San Diego, San Diego
University of California, Irvine, Orange
Stanford University, Palo Alto
Seattle Children's Hospital, Seattle
Boston Children's Hospital, Boston
St. Joseph's University Medical Center, Paterson
The Queen Elizabeth University, Glasgow
Hull and East Yorkshire Hospitals NHS Trust, Hull
Birmingham Women's and Children's Hospital, Birmingham
Fulbourn Hospital, Cambridge
Aintree University Hospital NHS Foundation Trust, Liverpool
Royal London Hospital, London
Chelsea and Westminster Hospital, London
Hammersmith Hospital, London
Soleno Therapeutics, Inc.
INDUSTRY